Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
InMed Prognostics
Pune, Maharashtra, India
- Ownership
- Private
- Employees
- ~31
- Development stage
- Other
01
Overview
InMed Prognostics has developed and commercialized FDA 510(k)-cleared NeuroShield, an AI-powered MR volumetric brain analysis software that calculates brain volumes from 3D MR scans and provides age-, gender-, and ethnicity-adjusted reference ranges to support early detection and management of neurodegenerative and other neurological disorders.[1][2] The company is expanding its commercial product suite to CT brain, whole-body MRI wellness/athletic solutions, and lesion analysis for pancreatic and liver cancer.[1]
- Therapeutic areas
- RheumatologyNeurologyGastroenterology
- Modalities
- DeviceNon-pharmacological therapySoftware as a medical device
- Industry
- Medical Imaging
Beyond the preview
Go deeper on InMed Prognostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InMed Prognostics.